| Vol. 12.42 – 5 November, 2020 |
| |
|
|
| Bladder cancer cells were co-cultured with exosomes isolated from human umbilical cord MSCs over-expressing miR-139-5p. The intercellular transfer of miR-139-5p along with in vitro and in vivo functions was determined using gain- and loss-of-function approaches. [Oncogene] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Human umbilical cord MSCs and human umbilical vein endothelial cells were isolated from human umbilical cords and characterized by a series of experiments. Lentivirus vector encoding miRNA-126-3p was transfected into hucMSCs and verified by PCR. [Stem Cell Research & Therapy] |
|
|
|
| Investigators revealed remarkable changes of multiple metabolites, especially lipids, in ovarian tissues after premature ovarian insufficiency (POI) generation. Following the transplantation of clinical-grade human umbilical cord MSCs, POI mice exhibited significant improvements in body weight, sex hormone levels, estrous cycles, and reproductive capacity. [Stem Cell Research & Therapy] |
|
|
|
| 61 patients diagnosed with premature ovarian insufficiency participated in this study. Umbilical cord-MSCs were isolated and cultured according to GMP standards, and then transplanted to the patients’ ovary by orthotopic injection under the guidance of vaginal ultrasound. [Cell Proliferation] |
|
|
|
| Researchers found that CD45−CD34− MSCs obtained from umbilical cord tissue and blood of term births displayed differences in the combinatorial expression of key MSC markers CD105 and CD90. [Scientific Reports] |
|
|
|
| The expression of C-reactive protein in CCl4-injured rat livers was detected using qRT-PCR and Western blotting after transplantation of placenta-derived MSCs into rats. [International Journal of Stem Cells] |
|
|
|
| The authors indicated that intravenous injection of allogenic umbilical cord-MSCs without immunosuppression exerted beneficial effects in subacute spinal cord injury (SCI) and thus could be a useful therapy to improve the functional capacity among patients with SCI. [Spinal Cord] |
| |
|
|
|
| Investigators explore the literature on markers able to identify MSCs as well as the presence of these cells in the healthy periodontal ligament and chronic periapical lesions, highlighting their role in regenerative medicine and implications in the progression of these lesions. [Acta Histochemica] |
|
|
|
|
| Bone Therapeutics and Catalent Pharma Solutions, Inc. announced the signing of share purchase and supply agreements to streamline and economize the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic cell therapy product and will enable Bone Therapeutics to focus its strategy on the development of products from its differentiated MSC platform of cell and gene therapeutic targets for orthopedics and other indications. [Bone Therapeutics] |
|
|
|
| IMAC Holdings, Inc. announced it is opening enrollment in its Phase I clinical trial for its investigational compound utilizing umbilical cord-derived allogenic MSCs for the treatment of bradykinesia, or the gradual slowing and loss of spontaneous body movement, due to Parkinson’s disease. [IMAC Holdings, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| December 2 – December 4 Virtual |
|
|
|
|
|
| United States Drug Testing Laboratories, Inc. – Des Plaines, Illinois, United States |
|
|
|
| National University of Ireland Galway – Galway, Ireland |
|
|
|
| University of Navarra – Pamplona, Spain |
|
|
|
| Sanford Research – Sioux Falls, South Dakota, United States |
|
|
|
| The University of Chicago – Chicago, Illinois, United States |
|
|
|
|